Phase 3 Heart Disease Trial, Recruiting NCT06742567 Sponsor: National Institute of Cardiovascular Diseases, Pakistan Condition: Heart Disease
Back to Heart Disease

Phase 3 Heart Disease Trial, Recruiting

NCT06742567
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 65 years old
  • You are currently having a type of heart attack called an "anterior STEMI" (a serious blockage in a specific artery at the front of the heart)
  • Tests show your heart's pumping strength is severely reduced (the heart is pumping less than 35% of its normal capacity), with part of the heart wall not moving properly or bulging outward
  • There is no blood clot found inside your heart's main pumping chamber

Who may not be able to join:

  • You have had a previous heart attack in the same area of the heart, or have had a procedure to open the same heart artery before
  • You are in cardiogenic shock (your heart is so weak it cannot pump enough blood to support your body)
  • You have a blood clot inside your heart's main pumping chamber
  • You have severe kidney disease (confirmed with trial site) or are currently on dialysis
  • You have recently had bleeding in the brain, a major bleed that needed a blood transfusion, or your platelet count (cells that help blood clot) is below 100,000
  • You have had a stroke within the past three months
  • You have an irregular heart rhythm called atrial fibrillation, or any other condition that requires you to take long-term blood thinners
  • You are pregnant or have a blood or bone marrow disorder

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Abdul Hakeem Professor of Cardiology, Director Cardiac Catheterization Labs, MD FACC FSCAI FASE, NICVD

Phone: +92 3355554342

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
National Institute of Cardiovascular Diseases, Pakistan
Registry
ClinicalTrials.gov
Start date
2 December 2024
Est. completion
30 November 2025

Where this trial is recruiting

🇵🇰 Pakistan

Primary endpoints

Incidence of LV thrombus formation in the treatment arm vs. control group

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov